Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Ccr8em1/Cya
Common Name:
Ccr8-KO
Product ID:
S-KO-01549
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Ccr8-KO
Strain ID
KOCMP-12776-Ccr8-B6J-VA
Gene Name
Ccr8
Product ID
S-KO-01549
Gene Alias
C-C; C-C CKR-8; CC-CKR-8; CCR-8; CKR-8; Cmkbr8; mCCR8
Background
C57BL/6JCya
NCBI ID
12776
Modification
Conventional knockout
Chromosome
9
Phenotype
MGI:1201402
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Ccr8em1/Cya mice (Catalog S-KO-01549) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000048777
NCBI RefSeq
NM_007720
Target Region
Exon 2
Size of Effective Region
~1.0 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Ccr8, the CC chemokine receptor 8, is a key molecule involved in immune cell regulation. It is expressed on certain immune cell subsets, and its ligands are CC-motif chemokines. Ccr8-mediated signaling may be involved in cell migration and immune response-related pathways, playing an important role in the immune system [4].

Multiple studies have explored the role of Ccr8 in the context of tumors. In mouse models of non-small cell lung carcinoma (NSCLC), single-cell RNA-sequencing identified a tumor-infiltrating regulatory T cell (Treg) population uniquely expressing Ccr8 along with Treg activation markers [1]. Depletion of Ccr8+ Tregs in mouse tumor models, either through an Fc-optimized anti-CCR8 antibody or other cell-depleting anti-CCR8 monoclonal antibodies, led to effective antitumor immunity. This was often accompanied by the expansion of CD8+ effector T cells, and in some cases, synergized with anti-PD-1 therapy. The depletion was tumor-Treg-restricted, sparing CCR8+ T cells in other tissues [1,2,3,6,7]. In a glioblastoma mouse model, lactate accumulation upregulated Ccr8 expression, and inhibiting lactate generation reduced tumor-infiltrating CCR8+ Tregs, enhancing CAR-T therapy efficacy [5].

In conclusion, Ccr8 is a crucial regulator in the immune response, especially in the tumor microenvironment. Studies using mouse models have revealed that targeting Ccr8 for the depletion of tumor-infiltrating Tregs can evoke potent antitumor immunity with long-lasting memory and without severe autoimmunity, suggesting its potential as a therapeutic target for cancer immunotherapy [1,2,3,6,7,8,9].

References:

1. Van Damme, Helena, Dombrecht, Bruno, Kiss, Máté, Laoui, Damya, Van Ginderachter, Jo Agnes. . Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy. In Journal for immunotherapy of cancer, 9, . doi:10.1136/jitc-2020-001749. https://pubmed.ncbi.nlm.nih.gov/33589525/

2. Campbell, Joseph R, McDonald, Bryan R, Mesko, Paul B, Jain, Renu, Lan, Ruth Y. 2021. Fc-Optimized Anti-CCR8 Antibody Depletes Regulatory T Cells in Human Tumor Models. In Cancer research, 81, 2983-2994. doi:10.1158/0008-5472.CAN-20-3585. https://pubmed.ncbi.nlm.nih.gov/33757978/

3. Kidani, Yujiro, Nogami, Wataru, Yasumizu, Yoshiaki, Ohkura, Naganari, Sakaguchi, Shimon. . CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. In Proceedings of the National Academy of Sciences of the United States of America, 119, . doi:10.1073/pnas.2114282119. https://pubmed.ncbi.nlm.nih.gov/35140181/

4. Korbecki, Jan, Grochans, Szymon, Gutowska, Izabela, Barczak, Katarzyna, Baranowska-Bosiacka, Irena. 2020. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands. In International journal of molecular sciences, 21, . doi:10.3390/ijms21207619. https://pubmed.ncbi.nlm.nih.gov/33076281/

5. Sun, Ting, Liu, Bin, Li, Yanyan, Yu, Dingjia, Yang, Wei. 2023. Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. In Journal of experimental & clinical cancer research : CR, 42, 253. doi:10.1186/s13046-023-02815-w. https://pubmed.ncbi.nlm.nih.gov/37770937/

6. Nagira, Yoji, Nagira, Morio, Nagai, Ryohei, Wada, Hisashi, Tanaka, Hidekazu. . S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells. In Molecular cancer therapeutics, 22, 1063-1072. doi:10.1158/1535-7163.MCT-22-0570. https://pubmed.ncbi.nlm.nih.gov/37420296/

7. Weaver, Jessica D, Stack, Edward C, Buggé, Joshua A, Depis, Fabien, Gostissa, Monica. 2022. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. In Oncoimmunology, 11, 2141007. doi:10.1080/2162402X.2022.2141007. https://pubmed.ncbi.nlm.nih.gov/36352891/

8. Wen, Yuanjia, Xia, Yu, Yang, Xiangping, Li, Huayi, Gao, Qinglei. 2025. CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells. In Trends in immunology, 46, 153-165. doi:10.1016/j.it.2025.01.001. https://pubmed.ncbi.nlm.nih.gov/39890548/

9. Moser, Bernhard. 2022. Chemokine Receptor-Targeted Therapies: Special Case for CCR8. In Cancers, 14, . doi:10.3390/cancers14030511. https://pubmed.ncbi.nlm.nih.gov/35158783/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest